We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » GI Dynamics’ EndoBarrier Meets Glycemic Control Endpoints in Diabetes Study
GI Dynamics’ EndoBarrier Meets Glycemic Control Endpoints in Diabetes Study
GI Dynamics’ announced final data from a multisite clinical study of its experimental EndoBarrier system, saying it met its endpoints in glycemic control efficacy and serious adverse events (SAE). Data also show clinically significant weight loss, the Boston-based company said.